scholarly journals Lanthanum-Induced Radiopaque Intestinal Precipitates: A Potential Cause of Intestinal Foreign Bodies

2019 ◽  
Vol 2019 ◽  
pp. 1-3 ◽  
Author(s):  
Jason Galo ◽  
Bianca Madrid ◽  
Warren Kupin
Keyword(s):  
Chronic Kidney Disease ◽  
Differential Diagnosis ◽  
Kidney Disease ◽  
Phosphate Binder ◽  
Foreign Bodies ◽  
Medical Resources ◽  
Benign Condition ◽  
X Ray ◽  
Soft Metal ◽  
Elemental Form

Lanthanum carbonate is a commonly prescribed oral phosphate binder for use in patients with acute or chronic kidney disease. The elemental form of lanthanum is a soft metal, which will appear radiopaque on a standard X-ray radiograph. This case report illustrates the potential for Lanthanum to masquerade as multiple radiopaque intestinal foreign bodies, leading to the extensive mobilization of medical resources and consultations including serial X-ray monitoring, multiple consultants including acute care and colorectal surgery. Given the few published reports describing this finding in the literature, it is essential to consider Lanthanum precipitates in the differential diagnosis of radiopaque intestinal foreign bodies in patients with chronic kidney disease to avoid unnecessary utilization of medical resources for this predominantly benign condition.

scholarly journals MULTIPLE MYELOMA: CHALLENGES OF DIFFERENTIAL DIAGNOSIS (CLINICAL CASE)

2020 ◽  
Vol 73 (1) ◽  
pp. 203-207
Author(s):  
Iryna V. Baranova ◽  
Kateryna P. Postovitenko ◽  
Iryna A. Iliuk ◽  
Sergii P. Kolisnyk ◽  
Alla F. Gumeniuk ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Multiple Myeloma ◽  
Differential Diagnosis ◽  
Kidney Disease ◽  
Renal Insufficiency ◽  
Clinical Picture ◽  
Clinical Case ◽  
Clinical Observation ◽  
Screening Method ◽  
X Ray

The objective of our study was to interpret and discuss atypical multiple myeloma case. The article describes the case of clinical observation of a patient K, in which manifestations of chronic kidney disease and circulatory failure prevailed in clinical picture of the disease. The authors recommended an X-ray examination of skull and pelvic bones as a screening method suitable for elderly people with symptoms of chronic renal insufficiency and chronic bone and muscle pain resistant to treatment.

scholarly journals Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Anique D. ter Braake ◽  
◽  
Larissa P. Govers ◽  
Mieke J. Peeters ◽  
Arjan D. van Zuilen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vascular Calcification ◽  
Disease Risk ◽  
Statistical Significance ◽  
Cardiovascular Disease Risk ◽  
Magnesium Concentration ◽  
X Ray ◽  
Abdominal Aortic ◽  
Plasma Magnesium

Abstract Background Higher plasma magnesium concentrations are associated with reduced cardiovascular disease risk in chronic kidney disease (CKD) patients. The importance of plasma magnesium concentration for vascular calcification in earlier stages of CKD remains underexplored. This study investigated whether plasma magnesium is a determinant for the presence and severity of vascular calcification in moderate CKD. Methods Retrospective analysis was performed using abdominal aortic calcification (AAC) scores in 280 patients with stage 3 and 4 CKD enrolled in the MASTERPLAN trial. Lateral abdominal X-ray was used to evaluate AAC. Plasma magnesium concentration were measured over time. A zero-inflated Poisson model determined the association between plasma magnesium concentration and AAC. Results 79 out of 280 patients did not have AAC, and in patients with AAC the median calcification score was 3.5 (interquartile range: 0.0–8.6). The mean plasma magnesium concentration was 0.76 ± 0.10 mmol/L at baseline. A 0.1 mmol/L higher plasma magnesium concentration was associated with lower AAC of 0.07 point (95% CI -0.28 – 0.14). A 0.1 mmol/L higher plasma magnesium lowered the odds of detecting any AAC by 30% (OR = 0.63; 95% CI 0.29–1.37). After 1 year and 4 years (at time of X-ray) of follow-up this association was attenuated (OR = 0.93; 95% CI 0.61–1.43 and 0.93; 95% CI 0.60–1.45, respectively). None of these associations reached statistical significance. Conclusions Plasma magnesium concentration at baseline is not associated with the risk for future AAC. Interventions increasing magnesium to avoid vascular calcification may have greatest potential in early CKD stages prior to onset of vascular calcification.

Evaluating Sucralfate as a Phosphate Binder in Normal Cats and Cats with Chronic Kidney Disease

2016 ◽  
Vol 52 (1) ◽  
pp. 8-12 ◽  
Author(s):  
Jessica Quimby ◽  
Michael Lappin
Keyword(s):  
Chronic Kidney Disease ◽  
Side Effects ◽  
Kidney Disease ◽  
Urinary Excretion ◽  
Phosphate Binder ◽  
Fractional Excretion ◽  
Serum Phosphorus ◽  
Phosphorus Concentration ◽  
Apparent Lack ◽  
Fecal Phosphorus

Control of hyperphosphatemia is an important part of the management of chronic kidney disease (CKD). The purpose of this study was to determine the efficacy of sucralfate as a phosphate binder in normal cats and normophosphatemic CKD cats. A 500 mg sucralfate slurry was administered orally q 8 hr for 2 wk, and serum phosphorus, urine fractional excretion of phosphorus, and fecal phosphorus concentrations were measured. In normal cats treated with sucralfate, significant changes in serum phosphorus concentration or urinary excretion of phosphorus were not detected, and vomiting occurred after 14.7% of administrations. Of the five normophosphatemic cats with CKD treated with sucralfate, three experienced clinical decompensation, including vomiting, anorexia, constipation, and increased azotemia. Administration of sucralfate did not result in significant changes in fecal phosphorus concentration in these cats. The effects of sucralfate administration on serum phosphorus concentration and urinary excretion of phosphorus in CKD cats was difficult to determine because of dehydration and worsening azotemia associated with decompensation. Due to side effects and the apparent lack of efficacy of the medication, the study was discontinued. This study was unable to confirm efficacy of this sucralfate formulation as a phosphate binder, and side effects were problematic during the study.

Sign in / Sign up

Export Citation Format

Share Document